Compare Davita Inc (DVA) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Huntington Bancshares Incorporated — how do they compare? Davita Inc trades at $178.61 (market cap $11.38B), while Huntington Bancshares Incorporated trades at $17.76 (market cap $35.93B). The key difference: Huntington Bancshares Incorporated is far larger — about 3.2× Davita Inc's market cap, and Huntington Bancshares Incorporated pays a 3.49% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | HBAN | |
|---|---|---|
Market Cap | $11.38B | $35.93B |
Sector | Health | Financials |
52-Week High | $240.96 | $19.27 |
52-Week Low | $103.87 | $15.02 |
Enterprise Value | $24.10B | — |
Dividend Yield | — | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
HBAN trades at $17.60, up 0.28% today, with a bullish technical signal from moving averages and a consensus analyst price target of $19.78. Recent Q2 2026 earnings met estimates with EPS of $0.33, supported by net interest and fee income growth. The company targets an 18-19% ROTCE by 2027, though rising deposit costs present headwinds.
The outlook is cautiously optimistic, with valuation metrics like a P/E of 13.68 appearing reasonable. Upside potential exists if revenue growth and efficiency targets are met, but risks include margin pressure from higher funding costs and mixed earnings history. Institutional sentiment is balanced with 44.68% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
